HMP Global Learning Network

Hello, I'm Zobair Younossi. I'm chairman of the Global NASH MASH Council, as well as Professor of Medicine and Chairman of Global Center for Liver Outcomes and Policy Research at Georgetown University School of Medicine. I'm delighted to be here with you to talk about our recent publication in Clinical Gastroenterology and Hepatology that has to do with global consensus recommendation related to MASLD treatment, risk stratification, and other clinical aspects.

SAN CLEMENTE, CA — Reflow Medical, Inc. announces that the Medical University of Graz has enrolled the first patient in the DEEPER CHALLENGE clinical trial. This investigator-initiated, single-center, single-arm, prospective study, supported by a grant, investigates early vessel recoil following below-the-knee treatment using the Spur® Peripheral Retrievable Scaffold System in combination with a commercially available drug-coated balloon.

JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

News Key Takeaways CMS has released the CY 2027 proposed rule for the Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Payment Systems. If finalized, these rules would take effect on January 1, 2027. Comments will be accepted for a defined period before issuance of the final rules later this year.

JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

Dr Jessica Weiser discusses the FDA approval of bemotrizinol (Tinosorb S), the first new sunscreen active ingredient added to the US sunscreen monograph in more than 20 years. Learn how this next-generation UV filter enhances broad-spectrum protection, improves UVA coverage, and may benefit patients concerned about melasma, photoaging, pigmentation, and skin cancer prevention while expanding cosmetically elegant sunscreen options for diverse skin types. Transcript Hi, my name is Dr Jessica Weiser.

Clostridioides difficile infection (CDI) remains a major driver of disease flares, hospitalization, treatment failure, and surgery in patients with inflammatory bowel disease (IBD), according to an American Gastroenterological Association (AGA) expert review outlining best practice advice for diagnosis and management.

JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

A systematic review and meta-analysis published in BMJ Open Gastroenterology suggests that advanced combination therapy (ACT)—the use of two advanced therapies targeting different inflammatory pathways—may be associated with low rates of serious adverse events (SAEs) in adults with refractory inflammatory bowel disease (IBD).